SCHEMBL6901552

SCHEMBL6901552

CCOC(=O)CN(C(=O)CC)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.60
GAA P10253 1/20 0.54
TSHR P16473 2/20 0.49
ALDH1A1 P00352 2/20 0.49
GLA P06280 1/20 0.49
KDM4E B2RXH2 1/20 0.48
POLB P06746 2/20 0.47
TP53 P04637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.45
ATM Q13315 1/20 0.45
OPRM1 P35372 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
LTB4R2 Q9NPC1 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20169531 0.89 SMN1; SMN2 (0.59) SMN1; SMN2GAATSHRALDH1A1GLA
SCHEMBL4434199 0.87 SMN1; SMN2 (0.57) SMN1; SMN2GAATSHRALDH1A1GLA
SCHEMBL2635519 0.87 SMN1; SMN2 (0.57) SMN1; SMN2GAATSHRALDH1A1GLA
SCHEMBL6901524 0.87 MLYCD (0.50) SMN1; SMN2GAATSHRALDH1A1GLA
SCHEMBL5807041 0.87 SMN1; SMN2 (0.60) SMN1; SMN2GAATSHRALDH1A1GLA
Hydrochloric Acid SCHEMBL4434198 0.86 SMN1; SMN2 (0.56) SMN1; SMN2GAATSHRALDH1A1GLA
SCHEMBL9366543 0.86 SMN1; SMN2 (0.56) SMN1; SMN2GAATSHRALDH1A1GLA
SCHEMBL7174025 0.86 SMN1; SMN2 (0.56) SMN1; SMN2GAATSHRALDH1A1GLA
SCHEMBL11437661 0.85 SMN1; SMN2 (0.59) SMN1; SMN2GAATSHRALDH1A1GLA
SCHEMBL6382412 0.85 SMN1; SMN2 (0.59) SMN1; SMN2GAATSHRALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 SMN1; SMN2 4727/4885GAA 1037/4885TSHR 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.